Infliximab in severe steroid-refractory ulcerative colitis: a pilot study.

Abstract

Tumor necrosis factor-alpha (TNF alpha)-neutralization by infliximab has previously proven efficacious in chronic active Crohn's disease (CD). We performed an open-label pilot study of a single infusion of 5 mg/kg infliximab in six patients with severe active, steroid-refractory ulcerative colitis (UC). Clinical activity was evaluated according to Lichtiger… (More)

Topics

  • Presentations referencing similar topics